000			05509cam a2200445Ii 4500
001			95602
003			ES-MaUEC
005			20230102112712.0
006			m o d
007			cr cnu|||unuuu
008			170317s2017 au ob 001 0 eng d
020			_a3709148561
020			_a3709148588 _q(electronic bk.)
020			_a9783709148563
020			_a9783709148587 _q(electronic bk.)
020			_z9783709148563
040			_aN$T _cN$T _dN$T _dGW5XE _dEBLCP _dOCLCF _dYDX _dUAB _dOCLCO _dIOG _dCOO _dAZU _dUPM _dOCLCO _dMERER _dESU _dVT2 _dOCLCQ _dOCLCO _dJBG _dIAD _dOCLCO _dICW _dOCLCO _dICN _dOCLCO _dOTZ _dOCLCO _dOCLCQ _dOHI _dOCLCQ _dOCLCO _dU3W _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aRC377 _b2017 EB
066			_c(S
245	0	0	_aHealth issues in women with multiple sclerosis _cMaria K. Houtchens, A. Dessa Sadovnick, editors.
264		1	_aWien, Austria _bSpringer International Publishing _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
504			_aIncluye referencias bibliográficas e índice
505	0		_6880-01 _aForeword; Preface; Contents; 1: Genetic Considerations and Reproductive Planning in Women with MS; 1.1 Introduction; 1.2 Fertility, Obstetrical Management, and Safety of MSTherapies (Conception, Gestation, Breastfeeding); 1.3 Reproductive Decision-Making: Retrospective Data; 1.4 Reproductive Concerns of MS Patients; 1.4.1 Genetics of Multiple Sclerosis; 1.5 Reproductive Counseling in MS; 1.6 Pediatric MS; 1.7 Summary; References; 2: Fertility and Assisted Reproductive Techniques in Women with MS; 2.1 The Reproductive Cycle and Fertility/Infertility; 2.1.1 Fertility in General.
505	8		_a2.1.2 Ovarian Cycle; 2.1.3 Uterine Cycle; 2.2 Epidemiology of Female Fertility in Multiple Sclerosis; 2.3 Assisted Reproductive Techniques (ARTs) and MS; 2.3.1 ARTs andHormonal Approaches in General; 2.3.2 ARTs and MS: Existing Studies; 2.4 Concluding Remarks; References; 3: Pregnancy Considerations and Pregnancy Outcomes in Women with MS; 3.1 Introduction; 3.2 Pregnancy Considerations; 3.2.1 Times Have Changed for Pregnancy in MS; 3.2.2 Women of Childbearing Age Are Susceptible to Relapsing-Remitting MS; 3.2.3 Changing Temporal Trends in Female to Male Ratio of MS.
505	8		_a3.2.4 Women with MS Have a Milder Disease Course; 3.2.4.1 Disentangling Effects ofPhenotype, Gender, and Age of Clinical Onset; 3.2.4.2 Age at Onset in MS and Age at Pregnancy Overlap; 3.2.4.3 Evidence from Natural History Studies; 3.2.4.4 Evidence from MRI and Cognition Studies; 3.2.5 The Risk of MS in Relation to Parity Status; 3.2.6 MS Onset in Relation to Pregnancy; 3.2.7 Getting Pregnant with MS (Patient's Perspective); 3.2.7.1 Concerns; 3.2.7.2 Practices; 3.2.8 Final Comments; 3.3 Pregnancy Outcomes in MS; 3.3.1 Effect of MS onPregnancy, Delivery, and Birth Outcomes.
505	8		_a3.3.2 Effects ofPregnancy on MS (Until 2 Years After Delivery); 3.3.3 Effects of Breastfeeding on MS; 3.3.4 Effects of Epidural Anesthesia and Cesarian Delivery on MS; 3.3.5 Postpartum Emotional Distress andSocial Support; 3.3.6 Long-Term Effects of Pregnancy and Postpartum on MS (>2Years); 3.3.6.1 Relapse Rate, Disability, and Risk of Secondary Progression; 3.3.6.2 Time from Onset to Reach Ambulatory Disability Milestones; 3.3.6.3 Age of Reaching Ambulatory Disability Milestones; 3.3.7 How to Explain a Potential Beneficial Effect of Pregnancy?
520	3		_aThis book addresses specific concerns of females affected by multiple sclerosis, where women are disproportionally impacted by the disease. MS is an autoimmune disease of the central nervous system affecting young adults of reproductive age. This book presents the current understanding of genetic variables, hormonal influences, immunological milieu and neurological outcomes, discussing issues such as fertility, pregnancy management, and menopause, as well as end of life care and mortality in women with MS. With contributions by international experts, this interdisciplinary book will serve as a useful reference and guide for MS specialists, general neurologists, obstetricians/gynecologists, physicians in training, family practice doctors, clinical nurse specialists in multiple sclerosis, €and all other healthcare professionals involved in the care and treatment of women affected by MS.
650		7	_aEsclerosis múltiple _xTreatment. _2embne _0(OCoLC)fst01029038 _0 _9142007
700	1		_aHoutchens, Maria K., _eeditor literario
700	1		_aSadovnick, Adele D., _d1950- _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-7091-4858-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880	8		_6505-01/(S _a3.3.7.1 Metabolic and Immunological Changes; 3.3.7.2 Reproduction-Induced Neuroplasticity; 3.3.8 Final Comments (Sect. 3.3); References; 4: Treatment Considerations in Female MS Patients of Reproductive Age; 4.1 Contraceptive Considerations; 4.2 Pregnancy Planning; 4.3 Pregnancy Considerations; 4.4 Disease-Modifying Therapies and Reproduction; 4.4.1 DMT use during Pregnancy ; 4.4.1.1 Injectable DMTs; Glatiramer Acetate; Interferon-βs; 4.4.2 Oral DMTs; 4.4.2.1 Dimethyl Fumarate; 4.4.2.2 Fingolimod; 4.4.2.3 Teriflunomide; 4.4.3 Intravenous Monoclonal Antibodies.
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95602 _d95602 _x1